ZA200301639B - Non-steroidal inflammation inhibitors. - Google Patents
Non-steroidal inflammation inhibitors. Download PDFInfo
- Publication number
- ZA200301639B ZA200301639B ZA200301639A ZA200301639A ZA200301639B ZA 200301639 B ZA200301639 B ZA 200301639B ZA 200301639 A ZA200301639 A ZA 200301639A ZA 200301639 A ZA200301639 A ZA 200301639A ZA 200301639 B ZA200301639 B ZA 200301639B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- hydroxy
- benzoxazin
- amino
- trifluoromethyl
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims description 8
- 230000004054 inflammatory process Effects 0.000 title claims description 8
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 89
- -1 heteroaryl radical Chemical class 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 44
- 230000008569 process Effects 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 23
- 230000002757 inflammatory effect Effects 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 21
- 208000010668 atopic eczema Diseases 0.000 claims description 20
- 230000000172 allergic effect Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000002062 proliferating effect Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 12
- NUIZBGCUWTXJRW-UHFFFAOYSA-N 4-(2-bromo-3-hydroxyphenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(O)=C1Br NUIZBGCUWTXJRW-UHFFFAOYSA-N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000008177 pharmaceutical agent Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- JZAVYXZWFNKXJG-UHFFFAOYSA-N 2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(C(F)(F)F)C=C1 JZAVYXZWFNKXJG-UHFFFAOYSA-N 0.000 claims description 6
- AMNTZAJRQYSGSI-UHFFFAOYSA-N 4-(2,3-difluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)hexanamide Chemical compound C=1C=C(C(ON=C2C)=O)C2=CC=1NC(=O)C(O)(C(F)(F)F)CC(C)(CC)C1=CC=CC(F)=C1F AMNTZAJRQYSGSI-UHFFFAOYSA-N 0.000 claims description 6
- WXGHGFSCDARFCQ-UHFFFAOYSA-N 4-(2-acetamido-5-fluorophenyl)-2-hydroxy-4-methyl-n-(1-oxo-3h-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide Chemical compound CC(=O)NC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(=O)NC1=CC=C(C(=O)OC2)C2=C1 WXGHGFSCDARFCQ-UHFFFAOYSA-N 0.000 claims description 6
- LKOOMTLSZKAUCJ-UHFFFAOYSA-N 4-(2-acetamido-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound CC(=O)NC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(=O)NC1=CC=C2C(=O)ON=C(C)C2=C1 LKOOMTLSZKAUCJ-UHFFFAOYSA-N 0.000 claims description 6
- NJKIIKFLRNIFHD-UHFFFAOYSA-N 4-(2-bromo-3,5-difluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC(F)=C1Br NJKIIKFLRNIFHD-UHFFFAOYSA-N 0.000 claims description 6
- LKDUCHKMZJJSMQ-UHFFFAOYSA-N 4-(2-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1F LKDUCHKMZJJSMQ-UHFFFAOYSA-N 0.000 claims description 6
- OVUGUMQWUWCXMU-UHFFFAOYSA-N 4-(3,5-difluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC(F)=C1 OVUGUMQWUWCXMU-UHFFFAOYSA-N 0.000 claims description 6
- IQBZSTXPSANONE-UHFFFAOYSA-N 4-(3-chloro-2-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(Cl)=C1F IQBZSTXPSANONE-UHFFFAOYSA-N 0.000 claims description 6
- AMWKTALQLOCTEY-UHFFFAOYSA-N 4-[5-fluoro-2-(methanesulfonamido)phenyl]-2-hydroxy-4-methyl-n-(1-oxo-3h-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide Chemical compound C=1C=C2C(=O)OCC2=CC=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1NS(C)(=O)=O AMWKTALQLOCTEY-UHFFFAOYSA-N 0.000 claims description 6
- QRWDZUQNPDZMQR-UHFFFAOYSA-N 5-amino-4-methyl-6-[3,3,3-trifluoro-2-hydroxy-2-[[1-[2-(trifluoromethyl)phenyl]cyclobutyl]methyl]propanoyl]-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)C(F)(F)F)CCC1 QRWDZUQNPDZMQR-UHFFFAOYSA-N 0.000 claims description 6
- IYHOZRPCBYJYLG-UHFFFAOYSA-N 5-amino-4-methyl-6-[3,3,3-trifluoro-2-hydroxy-2-[[1-[2-(trifluoromethyl)phenyl]cyclopropyl]methyl]propanoyl]-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)C(F)(F)F)CC1 IYHOZRPCBYJYLG-UHFFFAOYSA-N 0.000 claims description 6
- UBYNLOWUHUUMRX-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2,4-dichlorophenyl)cyclopropyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC(Cl)=CC=2)Cl)CC1 UBYNLOWUHUUMRX-UHFFFAOYSA-N 0.000 claims description 6
- HGLIPPOOBHTGGU-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chloro-5-fluorophenyl)cyclobutyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=C(F)C=2)Cl)CCC1 HGLIPPOOBHTGGU-UHFFFAOYSA-N 0.000 claims description 6
- LYIZTUAMCXXRMO-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chloro-5-fluorophenyl)cyclopropyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=C(F)C=2)Cl)CC1 LYIZTUAMCXXRMO-UHFFFAOYSA-N 0.000 claims description 6
- MQKYRKNLWYUECH-UHFFFAOYSA-N 5-amino-6-[4-(2-chloro-3-fluorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(F)=C1Cl MQKYRKNLWYUECH-UHFFFAOYSA-N 0.000 claims description 6
- VAKLTJXFPRHRQF-UHFFFAOYSA-N 5-amino-6-[4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(F)C=C1C(F)(F)F VAKLTJXFPRHRQF-UHFFFAOYSA-N 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- WNHFVTWAARRUTJ-UHFFFAOYSA-N 4-(2-amino-5-fluorophenyl)-2-hydroxy-4-methyl-n-(1-oxo-3h-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide Chemical compound C=1C=C2C(=O)OCC2=CC=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1N WNHFVTWAARRUTJ-UHFFFAOYSA-N 0.000 claims description 5
- CAYKKCUYNICYFU-UHFFFAOYSA-N 5-amino-6-[4-(2,5-dichlorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(Cl)=CC=C1Cl CAYKKCUYNICYFU-UHFFFAOYSA-N 0.000 claims description 5
- QHDCDFOTGJDIBJ-UHFFFAOYSA-N 5-amino-6-[4-[5-fluoro-2-(trifluoromethyl)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1C(F)(F)F QHDCDFOTGJDIBJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 4
- BCXNZLIRXKTGNM-UHFFFAOYSA-N 2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)-4-(2,3,4-trifluorophenyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(F)C(F)=C1F BCXNZLIRXKTGNM-UHFFFAOYSA-N 0.000 claims description 4
- VDWWFLOAUXTOFA-UHFFFAOYSA-N 4-(2-bromo-3-methoxyphenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound COC1=CC=CC(C(C)(C)CC(O)(C(=O)NC=2C=C3C(C(ON=C3C)=O)=CC=2)C(F)(F)F)=C1Br VDWWFLOAUXTOFA-UHFFFAOYSA-N 0.000 claims description 4
- BZGUCRMYTFFSKH-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1Cl BZGUCRMYTFFSKH-UHFFFAOYSA-N 0.000 claims description 4
- CICLKCYNZNJDNN-UHFFFAOYSA-N 4-(2-fluoro-3-methoxyphenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound COC1=CC=CC(C(C)(C)CC(O)(C(=O)NC=2C=C3C(C(ON=C3C)=O)=CC=2)C(F)(F)F)=C1F CICLKCYNZNJDNN-UHFFFAOYSA-N 0.000 claims description 4
- NGGFWRFSAPXTFL-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Cl)C=C1F NGGFWRFSAPXTFL-UHFFFAOYSA-N 0.000 claims description 4
- XGLDVYJOFZDGMU-UHFFFAOYSA-N 4-(5-fluoro-2-nitrophenyl)-2-hydroxy-4-methyl-n-(1-oxo-3h-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide Chemical compound C=1C=C2C(=O)OCC2=CC=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1[N+]([O-])=O XGLDVYJOFZDGMU-UHFFFAOYSA-N 0.000 claims description 4
- NKVZAJQQGORVMB-UHFFFAOYSA-N 5-amino-4-methyl-6-[3,3,3-trifluoro-2-[[1-[5-fluoro-2-(trifluoromethyl)phenyl]cyclopropyl]methyl]-2-hydroxypropanoyl]-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=C(F)C=2)C(F)(F)F)CC1 NKVZAJQQGORVMB-UHFFFAOYSA-N 0.000 claims description 4
- QBUFKXHAIFPIKQ-UHFFFAOYSA-N 5-amino-4-methyl-6-[3,3,3-trifluoro-2-hydroxy-2-[[1-[2-(trifluoromethyl)phenyl]cyclohexyl]methyl]propanoyl]-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)C(F)(F)F)CCCCC1 QBUFKXHAIFPIKQ-UHFFFAOYSA-N 0.000 claims description 4
- GUFSBGAKPRTKTG-UHFFFAOYSA-N 5-amino-6-[2-hydroxy-4-methyl-2-(trifluoromethyl)-4-[2-(trifluoromethyl)phenyl]pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1C(F)(F)F GUFSBGAKPRTKTG-UHFFFAOYSA-N 0.000 claims description 4
- BZEINGJAZXMFTH-UHFFFAOYSA-N 5-amino-6-[4-(2,4-dichlorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Cl)C=C1Cl BZEINGJAZXMFTH-UHFFFAOYSA-N 0.000 claims description 4
- IXSOKKOLFMGIJH-UHFFFAOYSA-N 5-amino-6-[4-(2-chloro-3-hydroxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(O)=C1Cl IXSOKKOLFMGIJH-UHFFFAOYSA-N 0.000 claims description 4
- UDHHLKYKGBFSEE-UHFFFAOYSA-N 5-amino-6-[4-(2-chloro-4-fluorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(F)C=C1Cl UDHHLKYKGBFSEE-UHFFFAOYSA-N 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 150000005840 aryl radicals Chemical class 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- XBBMTLDJZXQHKN-UHFFFAOYSA-N 2,3-benzoxazin-1-one Chemical class C1=CC=C2C(=O)ON=CC2=C1 XBBMTLDJZXQHKN-UHFFFAOYSA-N 0.000 claims description 3
- JWWVMXAQAXQFKX-UHFFFAOYSA-N 2-[[4-(2-chloro-5-fluorophenyl)oxan-4-yl]methyl]-3,3,3-trifluoro-2-hydroxy-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)propanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=C(F)C=2)Cl)CCOCC1 JWWVMXAQAXQFKX-UHFFFAOYSA-N 0.000 claims description 3
- JIADDUBQHRHLKK-UHFFFAOYSA-N 2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)-4-(2,3,5-trifluorophenyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC(F)=C1F JIADDUBQHRHLKK-UHFFFAOYSA-N 0.000 claims description 3
- SIIAKILUARIHSZ-UHFFFAOYSA-N 4-(2-amino-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1N SIIAKILUARIHSZ-UHFFFAOYSA-N 0.000 claims description 3
- PXUAYHLRPKYRRN-UHFFFAOYSA-N 4-(2-bromo-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1Br PXUAYHLRPKYRRN-UHFFFAOYSA-N 0.000 claims description 3
- LLTOISLBDAWTME-UHFFFAOYSA-N 4-(2-ethenyl-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1C=C LLTOISLBDAWTME-UHFFFAOYSA-N 0.000 claims description 3
- PEFVTILMMHVTCD-UHFFFAOYSA-N 4-(3-fluoro-4-nitrophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C([N+]([O-])=O)C(F)=C1 PEFVTILMMHVTCD-UHFFFAOYSA-N 0.000 claims description 3
- RPHZWUZNWNHVQZ-UHFFFAOYSA-N 4-(5-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-n-(1-oxo-3h-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide Chemical compound CC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(=O)NC1=CC=C(C(=O)OC2)C2=C1 RPHZWUZNWNHVQZ-UHFFFAOYSA-N 0.000 claims description 3
- WQSWEPAFLAZJFN-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2,4-dichlorophenyl)cyclobutyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC(Cl)=CC=2)Cl)CCC1 WQSWEPAFLAZJFN-UHFFFAOYSA-N 0.000 claims description 3
- CJGQGWFNRXUOGY-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chloro-4-fluorophenyl)cyclopropyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC(F)=CC=2)Cl)CC1 CJGQGWFNRXUOGY-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 239000007818 Grignard reagent Substances 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 150000007514 bases Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 208000030172 endocrine system disease Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 150000004673 fluoride salts Chemical class 0.000 claims description 3
- 150000004795 grignard reagents Chemical class 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- JXIWSMPUNDCTJE-UHFFFAOYSA-N 4-(2,3-difluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(F)=C1F JXIWSMPUNDCTJE-UHFFFAOYSA-N 0.000 claims description 2
- WXAUKMWHPOXPCK-UHFFFAOYSA-N 4-(3-fluoro-4-nitrophenyl)-2-hydroxy-4-methyl-n-(1-oxo-3h-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide Chemical compound C=1C=C2C(=O)OCC2=CC=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C([N+]([O-])=O)C(F)=C1 WXAUKMWHPOXPCK-UHFFFAOYSA-N 0.000 claims description 2
- QCRGDJBPYAYILT-UHFFFAOYSA-N 4-(5-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound CC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(=O)NC1=CC=C2C(=O)ON=C(C)C2=C1 QCRGDJBPYAYILT-UHFFFAOYSA-N 0.000 claims description 2
- VOAJGRIDBWLLJI-UHFFFAOYSA-N 4-(5-fluoro-2-nitrophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1[N+]([O-])=O VOAJGRIDBWLLJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- IBJHGYJYTFUNMA-UHFFFAOYSA-N 2-hydroxy-4-methyl-4-(3-methyl-2-nitrophenyl)-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound CC1=CC=CC(C(C)(C)CC(O)(C(=O)NC=2C=C3C(C(ON=C3C)=O)=CC=2)C(F)(F)F)=C1[N+]([O-])=O IBJHGYJYTFUNMA-UHFFFAOYSA-N 0.000 claims 3
- QROCAKZRULCDAS-UHFFFAOYSA-N 3,3,3-trifluoro-2-[[1-(2-fluorophenyl)cyclopentyl]methyl]-2-hydroxy-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)propanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)F)CCCC1 QROCAKZRULCDAS-UHFFFAOYSA-N 0.000 claims 3
- SHZAGCLNAYBRNL-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chloro-4-fluorophenyl)cyclobutyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC(F)=CC=2)Cl)CCC1 SHZAGCLNAYBRNL-UHFFFAOYSA-N 0.000 claims 3
- JGLQMQDTLXJDRH-UHFFFAOYSA-N 5-amino-6-[4-(2,3-dichlorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(Cl)=C1Cl JGLQMQDTLXJDRH-UHFFFAOYSA-N 0.000 claims 3
- CHBCOOSCRPRLFN-UHFFFAOYSA-N 5-amino-6-[4-(2-chlorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1Cl CHBCOOSCRPRLFN-UHFFFAOYSA-N 0.000 claims 3
- HSTZEGAFCBTUFY-UHFFFAOYSA-N 2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-4-naphthalen-1-yl-2-(trifluoromethyl)pentanamide Chemical compound C1=CC=C2C(C(C)(C)CC(O)(C(=O)NC3=CC=C4C(=O)ON=C(C4=C3)C)C(F)(F)F)=CC=CC2=C1 HSTZEGAFCBTUFY-UHFFFAOYSA-N 0.000 claims 2
- INLQPJOOWSVYOQ-UHFFFAOYSA-N 2-[[1-(2-bromophenyl)cyclopropyl]methyl]-3,3,3-trifluoro-2-hydroxy-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)propanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)Br)CC1 INLQPJOOWSVYOQ-UHFFFAOYSA-N 0.000 claims 1
- CKEDUFCTAPFENH-UHFFFAOYSA-N 3,3,3-trifluoro-2-[[1-(2-fluorophenyl)cyclobutyl]methyl]-2-hydroxy-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)propanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)F)CCC1 CKEDUFCTAPFENH-UHFFFAOYSA-N 0.000 claims 1
- BZPIGNOBIWYXJB-UHFFFAOYSA-N 4-(2-cyano-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1C#N BZPIGNOBIWYXJB-UHFFFAOYSA-N 0.000 claims 1
- HXKPAXXMFIYYIV-UHFFFAOYSA-N 5-amino-6-[4-(2-chloro-6-fluorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=C(F)C=CC=C1Cl HXKPAXXMFIYYIV-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000001704 evaporation Methods 0.000 description 18
- 230000008020 evaporation Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 230000003110 anti-inflammatory effect Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 11
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 239000003862 glucocorticoid Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 229940037128 systemic glucocorticoids Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- JNANSXYFIASNKP-UHFFFAOYSA-N 4-(5-fluoro-2-methylphenyl)-4-methyl-2-oxopentanoic acid Chemical compound CC1=CC=C(F)C=C1C(C)(C)CC(=O)C(O)=O JNANSXYFIASNKP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- AIHBPTWEQLZXKN-UHFFFAOYSA-N 2-(5-fluoro-2-methylphenyl)-2-methylpropanal Chemical compound CC1=CC=C(F)C=C1C(C)(C)C=O AIHBPTWEQLZXKN-UHFFFAOYSA-N 0.000 description 5
- IEFAQDLMDRYGDV-UHFFFAOYSA-N 2-(5-fluoro-2-methylphenyl)-2-methylpropanenitrile Chemical compound CC1=CC=C(F)C=C1C(C)(C)C#N IEFAQDLMDRYGDV-UHFFFAOYSA-N 0.000 description 5
- MYMODMCNZNYHEN-UHFFFAOYSA-N 4-(5-fluoro-2-methylphenyl)-4-methyl-2-oxo-n-(1-oxo-3h-2-benzofuran-5-yl)pentanamide Chemical compound CC1=CC=C(F)C=C1C(C)(C)CC(=O)C(=O)NC1=CC=C(C(=O)OC2)C2=C1 MYMODMCNZNYHEN-UHFFFAOYSA-N 0.000 description 5
- WAHLLEJIFLHPRU-UHFFFAOYSA-N 4-(5-fluoro-2-nitrophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoic acid Chemical compound OC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1[N+]([O-])=O WAHLLEJIFLHPRU-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- BTGIHHAXRSTULB-UHFFFAOYSA-N 6-amino-2,3-benzoxazin-1-one Chemical compound C1=NOC(=O)C=2C1=CC(N)=CC=2 BTGIHHAXRSTULB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003152 gestagenic effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WDDNLHUORBUOJW-UHFFFAOYSA-N 4-(2-bromophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1Br WDDNLHUORBUOJW-UHFFFAOYSA-N 0.000 description 3
- SKTZRUDGYWSNNT-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC(F)=CC=C1Cl SKTZRUDGYWSNNT-UHFFFAOYSA-N 0.000 description 3
- WLCMXZNKRLUPAR-UHFFFAOYSA-N 4-(3-fluorophenyl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC=CC(F)=C1 WLCMXZNKRLUPAR-UHFFFAOYSA-N 0.000 description 3
- XTVCJDDEEYRMLB-UHFFFAOYSA-N 5-amino-6-[4-(2-chloro-3-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound COC1=CC=CC(C(C)(C)CC(O)(C(=O)C=2C(=C3C(C(ON=C3C)=O)=CC=2)N)C(F)(F)F)=C1Cl XTVCJDDEEYRMLB-UHFFFAOYSA-N 0.000 description 3
- LUCGXHAMVUCMCR-UHFFFAOYSA-N 5-amino-6-[4-(4-bromo-2-chlorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Br)C=C1Cl LUCGXHAMVUCMCR-UHFFFAOYSA-N 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940117173 croton oil Drugs 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- BGMKXQGWIYKASY-UHFFFAOYSA-N ethyl 4-(3-fluorophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(F)=C1 BGMKXQGWIYKASY-UHFFFAOYSA-N 0.000 description 3
- CYDQTFUVHYARGE-UHFFFAOYSA-N ethyl 4-(3-fluorophenyl)-4-methyl-2-oxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)(C)C1=CC=CC(F)=C1 CYDQTFUVHYARGE-UHFFFAOYSA-N 0.000 description 3
- ZIWSIVUIRILDBD-UHFFFAOYSA-N ethyl 4-(5-fluoro-2-nitrophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1[N+]([O-])=O ZIWSIVUIRILDBD-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- LSVOABCWYPCIFV-UHFFFAOYSA-N 2-(2-chloro-5-fluorophenyl)-2-methylpropanal Chemical compound O=CC(C)(C)C1=CC(F)=CC=C1Cl LSVOABCWYPCIFV-UHFFFAOYSA-N 0.000 description 2
- XQQQKRFAZMCLOF-UHFFFAOYSA-N 2-(2-chloro-5-fluorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC(F)=CC=C1Cl XQQQKRFAZMCLOF-UHFFFAOYSA-N 0.000 description 2
- LIRMNANQMPRURB-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-methylpropanal Chemical compound O=CC(C)(C)C1=CC=CC(F)=C1 LIRMNANQMPRURB-UHFFFAOYSA-N 0.000 description 2
- JCMIPICRZKCQAV-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=CC(F)=C1 JCMIPICRZKCQAV-UHFFFAOYSA-N 0.000 description 2
- NYUGEJMCBCEKOG-UHFFFAOYSA-N 3,3,3-trifluoro-2-hydroxy-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-[[1-(2,3,5-trifluorophenyl)cyclopropyl]methyl]propanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC1(C=2C(=C(F)C=C(F)C=2)F)CC1 NYUGEJMCBCEKOG-UHFFFAOYSA-N 0.000 description 2
- YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 description 2
- XCTRLFDSBIKQFG-UHFFFAOYSA-N 4-(4-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound CC1=CC(F)=CC=C1C(C)(C)CC(O)(C(F)(F)F)C(=O)NC1=CC=C2C(=O)ON=C(C)C2=C1 XCTRLFDSBIKQFG-UHFFFAOYSA-N 0.000 description 2
- RMZSSGUMMRFIRU-UHFFFAOYSA-N 4-(5-fluoro-2-methylphenyl)-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-oxopentanamide Chemical compound CC1=CC=C(F)C=C1C(C)(C)CC(=O)C(=O)NC1=CC=C2C(=O)ON=C(C)C2=C1 RMZSSGUMMRFIRU-UHFFFAOYSA-N 0.000 description 2
- ISMUWQMUWFPFBZ-UHFFFAOYSA-N 5-amino-3h-2-benzofuran-1-one Chemical compound NC1=CC=C2C(=O)OCC2=C1 ISMUWQMUWFPFBZ-UHFFFAOYSA-N 0.000 description 2
- VZCUBTWFYVNPGP-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chlorophenyl)cyclobutyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)Cl)CCC1 VZCUBTWFYVNPGP-UHFFFAOYSA-N 0.000 description 2
- ZCYSISZXLHQWQA-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chlorophenyl)cyclopentyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)Cl)CCCC1 ZCYSISZXLHQWQA-UHFFFAOYSA-N 0.000 description 2
- JGFOCVGKSMIKJH-UHFFFAOYSA-N 5-amino-6-[2-[[1-(2-chlorophenyl)cyclopropyl]methyl]-3,3,3-trifluoro-2-hydroxypropanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC1(C=2C(=CC=CC=2)Cl)CC1 JGFOCVGKSMIKJH-UHFFFAOYSA-N 0.000 description 2
- GOKZZBYKUAFXTH-UHFFFAOYSA-N 5-amino-6-[4-[5-chloro-2-(trifluoromethyl)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoyl]-4-methyl-2,3-benzoxazin-1-one Chemical compound NC1=C2C(C)=NOC(=O)C2=CC=C1C(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(Cl)=CC=C1C(F)(F)F GOKZZBYKUAFXTH-UHFFFAOYSA-N 0.000 description 2
- FKSFQJWXHXGGJM-UHFFFAOYSA-N 6-fluoro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(F)C=C2C(C)(C)CC(=O)NC2=C1 FKSFQJWXHXGGJM-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- AVICGFICSIKUSO-UHFFFAOYSA-N ethyl 4-(3-fluoro-4-nitrophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C([N+]([O-])=O)C(F)=C1 AVICGFICSIKUSO-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- CHJVAINAJREZKY-UHFFFAOYSA-N n-(4-fluorophenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=C(F)C=C1 CHJVAINAJREZKY-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- GHDOLZPTCKUXIL-UHFFFAOYSA-N tert-butyl 6-fluoro-4,4-dimethyl-2-oxo-3h-quinoline-1-carboxylate Chemical compound FC1=CC=C2N(C(=O)OC(C)(C)C)C(=O)CC(C)(C)C2=C1 GHDOLZPTCKUXIL-UHFFFAOYSA-N 0.000 description 2
- NSCKLQMICHJDBX-UHFFFAOYSA-N tert-butyl n-[4-fluoro-2-(4-hydroxy-2-methylbutan-2-yl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)C=C1C(C)(C)CCO NSCKLQMICHJDBX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- COYCHCYSJJZVQR-UHFFFAOYSA-N 2-(5-fluoro-2-methylphenyl)acetonitrile Chemical compound CC1=CC=C(F)C=C1CC#N COYCHCYSJJZVQR-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- QPPPPGJJLJDIGS-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(F)C=C1F QPPPPGJJLJDIGS-UHFFFAOYSA-N 0.000 description 1
- PMAHVVINAJZRAE-UHFFFAOYSA-N 4-(2,5-difluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1F PMAHVVINAJZRAE-UHFFFAOYSA-N 0.000 description 1
- IYRCWSNXZNRTBH-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-4-methyl-2-oxo-n-(1-oxo-2,3-benzoxazin-6-yl)pentanamide Chemical compound C=1C=C(C(ON=C2)=O)C2=CC=1NC(=O)C(=O)CC(C)(C)C1=CC(F)=CC=C1Cl IYRCWSNXZNRTBH-UHFFFAOYSA-N 0.000 description 1
- QRKVBRSIYURKBH-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-oxopentanamide Chemical compound C1=C2C(C)=NOC(=O)C2=CC=C1NC(=O)C(=O)CC(C)(C)C1=CC(F)=CC=C1Cl QRKVBRSIYURKBH-UHFFFAOYSA-N 0.000 description 1
- MEAWAEAOSJCLOL-UHFFFAOYSA-N 4-(2-ethyl-5-fluorophenyl)-2-hydroxy-4-methyl-n-(4-methyl-1-oxo-2,3-benzoxazin-6-yl)-2-(trifluoromethyl)pentanamide Chemical compound CCC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(=O)NC1=CC=C2C(=O)ON=C(C)C2=C1 MEAWAEAOSJCLOL-UHFFFAOYSA-N 0.000 description 1
- JVULEGRWLQCMPE-UHFFFAOYSA-N 4-(3-fluoro-4-nitrophenyl)-2-hydroxy-4-methyl-N-(1-oxo-3H-2-benzofuran-5-yl)-2-(trifluoromethyl)pentanamide 4-(3-fluoro-4-nitrophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoic acid Chemical compound FC=1C=C(C=CC1[N+](=O)[O-])C(CC(C(=O)O)(C(F)(F)F)O)(C)C.FC=1C=C(C=CC1[N+](=O)[O-])C(CC(C(=O)NC=1C=C2COC(=O)C2=CC1)(C(F)(F)F)O)(C)C JVULEGRWLQCMPE-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- PDSZQDJIKVTPHU-UHFFFAOYSA-N 4-methyl-2,3-benzoxazin-1-one Chemical compound C1=CC=C2C(C)=NOC(=O)C2=C1 PDSZQDJIKVTPHU-UHFFFAOYSA-N 0.000 description 1
- HEOQXHNKRXRCTO-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulene Chemical compound C1CCCCC2=CC=CC=C21 HEOQXHNKRXRCTO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 206010057380 Allergic keratitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 201000002015 Thyroid Crisis Diseases 0.000 description 1
- 206010043786 Thyrotoxic crisis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- VKIWONMJPOTZNB-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-ethoxyacetate Chemical compound CCOC(=O)C(OCC)P(=O)(OCC)OCC VKIWONMJPOTZNB-UHFFFAOYSA-N 0.000 description 1
- PGDNTWQSENCYST-UHFFFAOYSA-N ethyl 4-(3-fluoro-4-nitrophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate;ethyl 4-(5-fluoro-2-nitrophenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C([N+]([O-])=O)C(F)=C1.CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1[N+]([O-])=O PGDNTWQSENCYST-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- YTKZHDYSHIZVBH-UHFFFAOYSA-N heptane;oxolane;toluene Chemical compound C1CCOC1.CCCCCCC.CC1=CC=CC=C1 YTKZHDYSHIZVBH-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 208000028931 non-acquired combined pituitary hormone deficiency Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10038639A DE10038639A1 (de) | 2000-07-28 | 2000-07-28 | Nichtsteroidale Entzündungshemmer |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200301639B true ZA200301639B (en) | 2004-06-22 |
Family
ID=7651697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301639A ZA200301639B (en) | 2000-07-28 | 2003-02-27 | Non-steroidal inflammation inhibitors. |
Country Status (27)
Country | Link |
---|---|
US (3) | US6777409B2 (de) |
EP (1) | EP1309571A1 (de) |
JP (1) | JP2004505068A (de) |
KR (1) | KR20030019626A (de) |
CN (2) | CN1444570A (de) |
AU (2) | AU2001282009B2 (de) |
BG (1) | BG107488A (de) |
BR (1) | BR0112786A (de) |
CA (1) | CA2417444A1 (de) |
CZ (1) | CZ2003216A3 (de) |
DE (1) | DE10038639A1 (de) |
EA (1) | EA005926B1 (de) |
EE (1) | EE200300043A (de) |
HR (1) | HRP20030148A2 (de) |
HU (1) | HUP0301344A3 (de) |
IL (1) | IL154143A0 (de) |
MX (1) | MXPA02012933A (de) |
NO (1) | NO20030406L (de) |
NZ (1) | NZ523822A (de) |
PE (1) | PE20020230A1 (de) |
PL (1) | PL366336A1 (de) |
SK (1) | SK812003A3 (de) |
TW (1) | TWI282336B (de) |
UA (1) | UA77657C2 (de) |
WO (1) | WO2002010143A1 (de) |
YU (1) | YU5503A (de) |
ZA (1) | ZA200301639B (de) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10346940B3 (de) * | 2003-10-06 | 2005-06-16 | Schering Ag | Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
US7238707B2 (en) | 2000-07-28 | 2007-07-03 | Schering Ag | Substituted pentanols, a process for their production and their use as anti-inflammatory agents |
AU2003202216A1 (en) | 2002-01-14 | 2003-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
MXPA04008881A (es) * | 2002-03-11 | 2004-12-07 | Schering Ag | 5-{2- hidroxi-3 -[1-(3- trifluorometilfenil) -ciclopropil] -propionilamino}- ftalida y compuestos relacionados con actividad que modula el receptor de progesterona para utilizarse en control de fertilidad y terapia de reemplazo hormonal. |
EP1344776A1 (de) * | 2002-03-11 | 2003-09-17 | Schering Aktiengesellschaft | 5- 2-Hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalid- und 6- 2-Hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-on-Derivate mit progesteronrezeptor-modulierender Wirkung zur Anwendung in der Empfängnisverhütung, Hormonersatztherapie und zur Behandlung von gynäkologischen Störungen |
CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US6903215B2 (en) * | 2002-03-26 | 2005-06-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) * | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
US6897224B2 (en) * | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CN1678306A (zh) * | 2002-08-29 | 2005-10-05 | 贝林格尔·英格海姆药物公司 | 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3-(磺酰氨基乙基)-吲哚衍生物 |
EP1583745A1 (de) | 2003-01-03 | 2005-10-12 | Boehringer Ingelheim Pharmaceuticals Inc. | 1-propanol- und 1-propylaminderivate undderen verwendung als glucocorticoidliganden |
WO2004071389A2 (en) * | 2003-02-15 | 2004-08-26 | Glaxo Group Limited | Non-steroidal infalmmation inhibitors |
US20040224992A1 (en) * | 2003-02-27 | 2004-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
US20050090559A1 (en) * | 2003-07-01 | 2005-04-28 | Markus Berger | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents |
AU2004254205A1 (en) * | 2003-07-01 | 2005-01-13 | Schering Aktiengesellschaft | Heterocyclically substituted pentanol derivatives, method for the production thereof, and use thereof as anti-inflammatory agents |
UY28526A1 (es) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
WO2005034939A1 (de) | 2003-10-08 | 2005-04-21 | Schering Aktiengesellschaft | Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer |
DE10347385A1 (de) * | 2003-10-08 | 2005-05-12 | Schering Ag | Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
DE102004017662B3 (de) * | 2004-04-05 | 2005-12-08 | Schering Ag | Mehrfach substituierte Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
EP1675839B1 (de) | 2003-10-16 | 2007-07-11 | Boehringer Ingelheim Pharmaceuticals Inc. | Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US20080153859A1 (en) * | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
WO2006000401A1 (en) * | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
WO2006000398A1 (en) * | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
US20060084652A1 (en) * | 2004-09-09 | 2006-04-20 | Stefan Baeurle | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
DE102004044680B3 (de) * | 2004-09-09 | 2006-06-08 | Schering Ag | Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
US20060167025A1 (en) * | 2004-12-22 | 2006-07-27 | Markus Berger | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs |
DE102004063227A1 (de) * | 2004-12-22 | 2006-07-06 | Schering Ag | Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
US7635711B2 (en) | 2004-12-27 | 2009-12-22 | Boehringer-Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2006213674A (ja) * | 2005-02-07 | 2006-08-17 | Ube Ind Ltd | 4−ホルミルテトラヒドロピラン化合物の製法 |
DE102005014089A1 (de) * | 2005-03-22 | 2006-09-28 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
US20060229305A1 (en) * | 2005-03-22 | 2006-10-12 | Markus Berger | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
JP2006265173A (ja) * | 2005-03-24 | 2006-10-05 | Sumitomo Chemical Co Ltd | グルココルチコイド受容体リガンド結合ドメインとリガンドとの複合体を含む結晶 |
DE102005017301A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Substituierte Chromanderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
DE102005017326A1 (de) * | 2005-04-14 | 2007-03-29 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
DE102005018026B4 (de) * | 2005-04-14 | 2006-12-21 | Schering Ag | Substituierte Styrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
DE102005017286B3 (de) * | 2005-04-14 | 2006-12-28 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
MX2007013450A (es) | 2005-04-29 | 2008-01-21 | Wyeth Corp | Procedimniento de preparacion de oxindoles y tio-oxindoles 3,3-disustituidos. |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7408060B2 (en) * | 2005-06-24 | 2008-08-05 | Schering Ag | Nonsteroidal progesterone receptor modulators |
EP2532679B1 (de) | 2005-10-21 | 2017-04-12 | Novartis AG | Menschliche Antikörper gegen IL13 und therapeutische Verwendungen |
JP4980366B2 (ja) * | 2005-12-09 | 2012-07-18 | エフ.ホフマン−ラ ロシュ アーゲー | 抗炎症剤としてのグルココルチコイド受容体モジュレーター |
EP1960351B1 (de) * | 2005-12-09 | 2013-06-19 | F.Hoffmann-La Roche Ag | Propionamidverbindungen als entzündungshemmende mittel |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EP1834948A1 (de) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
AU2007242851A1 (en) * | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Novel compounds |
KR20080110925A (ko) | 2006-04-21 | 2008-12-19 | 노파르티스 아게 | 아데노신 a2a 수용체 효능제로서 사용하기 위한 퓨린 유도체 |
US7390772B2 (en) * | 2006-05-18 | 2008-06-24 | International Flavor & Fragrances Inc. | 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations |
EP1878717A1 (de) | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzylamine, Verfahren zu ihrer Herstellung und ihre Anwendung als Entzündungshemmer |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
KR20090097908A (ko) | 2006-12-06 | 2009-09-16 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코코르티코이드 모사물, 이의 제조 방법, 이의 약제학적 조성물 및 용도 |
UY30805A1 (es) * | 2006-12-21 | 2008-07-31 | Bayer Schering Pharma Ag | Moduladores no esteroides de receptores de progesterona |
EA016199B1 (ru) | 2007-01-10 | 2012-03-30 | Айрм Ллк | Соединения и композиции как ингибиторы активирующей канал протеазы |
EP1958934A1 (de) * | 2007-02-16 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphtalenylamide, ein Herstellungsverfahren dafür und ihre Verwendung als entzündungshemmende Mittel |
US8318935B2 (en) | 2007-05-07 | 2012-11-27 | Novartis Ag | Organic compounds 75074 |
US7858666B2 (en) | 2007-06-08 | 2010-12-28 | Mannkind Corporation | IRE-1α inhibitors |
EP2062880A1 (de) * | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluor-2-hydroxy-1-arylpropyl)amino]-1H-chinolin-2-one, Verfahren zu ihrer Herstellung und ihre Verwendung als entzündungshemmende Wirkstoffe |
DE102007058747A1 (de) * | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
JP5455922B2 (ja) | 2007-12-10 | 2014-03-26 | ノバルティス アーゲー | 有機化合物 |
ES2442930T3 (es) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pirimidinas como inhibidores de cinasas |
KR20110020902A (ko) | 2008-06-06 | 2011-03-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코코르티코이드 유사체, 이의 제조방법, 약제학적 조성물 및 이의 용도 |
WO2009150137A2 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
EP2149558A1 (de) | 2008-07-21 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-one, ein Verfahren zu deren Herstellung und deren Verwendung als Entzündungshemmer |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
SI2379507T1 (sl) | 2008-12-30 | 2014-02-28 | Pulmagen Therapeutics (Inflammation) Limited | Spojine sulfonamida za zdravljenje respiratornih motenj |
DK2391366T3 (da) | 2009-01-29 | 2013-01-07 | Novartis Ag | Substituerede benzimidazoler til behandling af astrocytomer |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
AU2010280323A1 (en) | 2009-07-31 | 2012-03-08 | Cadila Healthcare Limited | Novel compounds as modulators of glucocorticoid receptors |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
KR20120089463A (ko) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | 헤테로시클릭 옥심 화합물 |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
EP2755976B1 (de) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
CA2868202C (en) | 2012-04-03 | 2021-08-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
RU2483723C1 (ru) * | 2012-04-25 | 2013-06-10 | Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения эндокринной офтальмопатии |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
EP3007697B1 (de) | 2013-06-14 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1-inhibitoren zur induzierung von bronchodilatation |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
AU2014391610B2 (en) | 2014-04-24 | 2018-01-25 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
CN107530435A (zh) | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
JP6754533B2 (ja) | 2015-03-30 | 2020-09-16 | コーセプト セラピューティクス, インコーポレイテッド | 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用 |
JP6768789B2 (ja) | 2015-08-13 | 2020-10-14 | コーセプト セラピューティクス, インコーポレイテッド | Acth依存性クッシング症候群を鑑別診断する方法 |
WO2017127448A1 (en) | 2016-01-19 | 2017-07-27 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
EP3569228A1 (de) | 2018-05-17 | 2019-11-20 | Association pour la recherche à l'IGBMC (ARI) | Nichtsteroidale selektive glucocorticoid-rezeptor-agonistische modulatoren (segramme) und verwendungen davon |
ES2932076T3 (es) * | 2017-10-27 | 2023-01-11 | Association Pour La Rech A Ligbmc Ari | Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
US20220306617A1 (en) | 2019-08-28 | 2022-09-29 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
WO2022130015A2 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
DE19856475A1 (de) * | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
JP3464405B2 (ja) * | 1999-02-18 | 2003-11-10 | 阪神化成工業株式会社 | 多層薄肉容器 |
-
2000
- 2000-07-28 DE DE10038639A patent/DE10038639A1/de not_active Withdrawn
-
2001
- 2001-07-23 UA UA2003021765A patent/UA77657C2/uk unknown
- 2001-07-23 BR BR0112786-1A patent/BR0112786A/pt not_active IP Right Cessation
- 2001-07-23 CN CN01813490.4A patent/CN1444570A/zh active Pending
- 2001-07-23 NZ NZ523822A patent/NZ523822A/en unknown
- 2001-07-23 YU YU5503A patent/YU5503A/sh unknown
- 2001-07-23 AU AU2001282009A patent/AU2001282009B2/en not_active Ceased
- 2001-07-23 PL PL01366336A patent/PL366336A1/xx not_active Application Discontinuation
- 2001-07-23 EA EA200300105A patent/EA005926B1/ru not_active IP Right Cessation
- 2001-07-23 KR KR10-2003-7001215A patent/KR20030019626A/ko not_active Application Discontinuation
- 2001-07-23 CA CA002417444A patent/CA2417444A1/en not_active Abandoned
- 2001-07-23 SK SK81-2003A patent/SK812003A3/sk not_active Application Discontinuation
- 2001-07-23 CN CNA2006101290933A patent/CN1915231A/zh active Pending
- 2001-07-23 WO PCT/EP2001/008501 patent/WO2002010143A1/de not_active Application Discontinuation
- 2001-07-23 CZ CZ2003216A patent/CZ2003216A3/cs unknown
- 2001-07-23 EP EP01960536A patent/EP1309571A1/de not_active Withdrawn
- 2001-07-23 EE EEP200300043A patent/EE200300043A/xx unknown
- 2001-07-23 MX MXPA02012933A patent/MXPA02012933A/es not_active Application Discontinuation
- 2001-07-23 JP JP2002515874A patent/JP2004505068A/ja not_active Withdrawn
- 2001-07-23 HU HU0301344A patent/HUP0301344A3/hu unknown
- 2001-07-23 AU AU8200901A patent/AU8200901A/xx active Pending
- 2001-07-23 IL IL15414301A patent/IL154143A0/xx unknown
- 2001-07-27 TW TWNONSTEROIA patent/TWI282336B/zh not_active IP Right Cessation
- 2001-07-27 US US09/916,195 patent/US6777409B2/en not_active Expired - Fee Related
- 2001-07-27 PE PE2001000766A patent/PE20020230A1/es not_active Application Discontinuation
-
2003
- 2003-01-22 BG BG107488A patent/BG107488A/bg unknown
- 2003-01-27 NO NO20030406A patent/NO20030406L/no unknown
- 2003-02-27 ZA ZA200301639A patent/ZA200301639B/en unknown
- 2003-02-28 HR HR20030148A patent/HRP20030148A2/hr not_active Application Discontinuation
-
2004
- 2004-06-24 US US10/874,485 patent/US7166592B2/en not_active Expired - Fee Related
-
2005
- 2005-10-20 US US11/253,690 patent/US7129270B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200301639B (en) | Non-steroidal inflammation inhibitors. | |
US6323199B1 (en) | Nonsteroidal anti-inflammatory agents | |
JP2006512382A (ja) | 非ステロイド性抗炎症剤 | |
EA028232B1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
FR2567885A1 (fr) | Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant | |
WO2021161105A1 (en) | P2x3 modulators | |
KR100647726B1 (ko) | 피리다진-3-온 유도체 및 이를 함유하는 의약 | |
ZA200603601B (en) | 1-(quinoline amino) and 1-(isoquinoline amino)-substituted pentan-2-ols, method for their production and their use as anti-inflammatories | |
US7112584B2 (en) | Nonsteroidal antiinflammatory agents | |
JP2002504547A (ja) | 新規複素環ジアリールメチレン誘導体、その調製方法及び治療におけるその使用 | |
JPS60130567A (ja) | 3−置換−2−フエニルインド−ル誘導体 | |
CN107973780B (zh) | 一种取代的烯烃类化合物及其制备方法和用途 | |
JPH10511115A (ja) | 新規イミダゾールリポキシゲナーゼ阻害剤 | |
JPH0665241A (ja) | 縮合イミダゾール化合物、その製造法及び剤 | |
JPH03284674A (ja) | インドール誘導体およびそれらを有効成分とする抗癌剤 |